TELOTRISTAT ETIPRATE
| Brand name | XERMELO |
|---|---|
| Active ingredient | TELOTRISTAT ETIPRATE |
| Strength | EQ 250MG BASE |
| Dosage form | TABLET |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | February 2017 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 7709493 | February 2031 | substance |
| 8193204 | February 2031 | substance |
| 8653094 | December 2028 | use U-1979 |
| 7968559 | December 2027 | use U-1979 |
| 7553840 | December 2027 | substance |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.